Literature DB >> 14523682

Histopathological features of L-asparaginase-induced liver disease.

Sunati Sahoo1, John Hart.   

Abstract

We studied the histopathological changes of liver in four patients who developed hepatomegaly and abnormal liver chemistry tests 2 to 20 days following administration of L-asparaginase as a part of a combination chemotherapy regimen for treatment of acute lymphoblastic leukemia. The severity of the liver disease due to L-asparaginase was unpredictable. One patient developed acute fulminant hepatic failure and required liver transplantation. The most consistent pathological change, observed in all four cases, was diffuse steatosis. Other changes included patchy hepatocyte necrosis, mixed inflammatory cell infiltrates in the portal tracts, and variable degrees of hepatocellular, or canalicular cholestasis, or a combination of these.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523682     DOI: 10.1055/s-2003-42647

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  20 in total

Review 1.  Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.

Authors:  David O Riley; Jenna M Schlefman; Hans Christoph Vitzthum Von Eckstaedt V; Amy L Morris; Michael K Keng; Firas El Chaer
Journal:  Curr Hematol Malig Rep       Date:  2021-05-12       Impact factor: 3.952

Review 2.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

3.  Autoregressive moving average modeling for hepatic iron quantification in the presence of fat.

Authors:  Aaryani Tipirneni-Sajja; Axel J Krafft; Ralf B Loeffler; Ruitian Song; Armita Bahrami; Jane S Hankins; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2019-02-13       Impact factor: 4.813

4.  A defect in the activities of Δ and Δ desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease.

Authors:  Undurti N Das
Journal:  World J Diabetes       Date:  2011-11-15

5.  Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.

Authors:  Natasha Kamal; Christopher Koh; Niharika Samala; Robert J Fontana; Andrew Stolz; Francisco Durazo; Paul H Hayashi; Elizabeth Phillips; Tongrong Wang; Jay H Hoofnagle
Journal:  Hepatol Int       Date:  2019-08-07       Impact factor: 6.047

6.  Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia.

Authors:  Saman K Hashmi; Shoba A Navai; Tiffany M Chambers; Michael E Scheurer; M John Hicks; Rachel E Rau; Maria M Gramatges
Journal:  Pediatr Blood Cancer       Date:  2019-11-17       Impact factor: 3.167

7.  GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.

Authors:  Gabriel J Wilson; Brittany A Lennox; Pengxiang She; Emily T Mirek; Rana J T Al Baghdadi; Michael E Fusakio; Joseph L Dixon; Gregory C Henderson; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-12-09       Impact factor: 4.310

8.  Cell-cycle inhibition by Helicobacter pylori L-asparaginase.

Authors:  Claudia Scotti; Patrizia Sommi; Maria Valentina Pasquetto; Donata Cappelletti; Simona Stivala; Paola Mignosi; Monica Savio; Laurent Roberto Chiarelli; Giovanna Valentini; Victor M Bolanos-Garcia; Douglas Scott Merrell; Silvia Franchini; Maria Luisa Verona; Cristina Bolis; Enrico Solcia; Rachele Manca; Diego Franciotta; Andrea Casasco; Paola Filipazzi; Elisabetta Zardini; Vanio Vannini
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

9.  Obesity challenges the hepatoprotective function of the integrated stress response to asparaginase exposure in mice.

Authors:  Inna A Nikonorova; Rana J T Al-Baghdadi; Emily T Mirek; Yongping Wang; Michael P Goudie; Berish B Wetstein; Joseph L Dixon; Christopher Hine; James R Mitchell; Christopher M Adams; Ronald C Wek; Tracy G Anthony
Journal:  J Biol Chem       Date:  2017-02-27       Impact factor: 5.157

10.  Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.

Authors:  Jessica L Sea; Etan Orgel; Ting Chen; Rebecca L Paszkiewicz; Abigail S Krall; Matthew J Oberley; Linsey Stiles; Steven D Mittelman
Journal:  Leuk Lymphoma       Date:  2019-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.